by Sean Hughes | Oct 1, 2016 | EPO
Introduction In decisions G 2/12 (“Broccoli II”) and G 2/13 (“Tomatoes II”), the Enlarged Board of Appeal (EBA) of the European Patent Office (EPO) found that plants and products thereof, e.g. seeds and fruits, are patentable. This is the case...
by David Eyre | Jan 1, 2016 | US & International
Executive Summary / Practice Points Stem cell technologies promise to be the next transformative medical technology offering therapies for conditions and diseases that are currently beyond medical science by creating replacement or supplementary tissues for a patient....
by David Eyre | Jan 1, 2015 | EPO
Background Following C-34/10, any non-fertilised human ovum for which division and further development are stimulated by parthenogenesis was to be considered a “human embryo”. Such a non-fertilised and stimulated human ovum is called a parthenote. The CJEU’s ruling in...
by David Eyre | Sep 1, 2014 | EPO
The scope for patenting stem cell-based inventions in Europe was dealt a blow by the judgement of the CJEU in Brüstle vs Greenpeace (C 34/10)1. The practical result of this judgement was that the earliest date from which the EPO would acknowledge that morally...
by George Schlich | Jun 1, 2013 | EPO
As background, Prof. Dr. Brüstle has parallel European and German patents relating to neural precursor cells, derivable from cells obtained from human embryos (as well as other sources). The patents are notable in that they were initially objected to in both...
Recent Comments